GHRS GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Is GH Research (GHRS) Trading At A Premium To Fair Value? GH Research stock has delivered strong gains over the past few years, yet its latest valuation checks suggest the shares may now be priced on the expensive side rather than offering clear value. Over the last 3 years, GH Research has returned 121.2% which puts the recent share price firmly in the spotlight for valuation focused investors. The key support for the current price can come from how investors view GH Research's ability to convert its research pipeline into sustainable cash flows,... | ||
 CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings. | ||
 Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading. | ||
Why Psychedelic stocks are surging today Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space. | ||
 GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS) GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha | ||
 The Race to Commercialize the World’s Most Powerful Psychedelic An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison. | ||
 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc.... | ||